Skip to main content

Takeda Pharmaceutical Co Ltd

TKPHF
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001395064

In the last 90 days, Takeda Pharmaceutical Co Ltd insiders filed 0 open-market purchases and 6 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Other share classesTAK

Key figures

Market capNo recent share count in SEC filings
–
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $5.52M in total
6
13F holdersQ2 2026
0
13F valueReported value at the end of Q2 2026
$0
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in JPY.

Revenue, FY2025
JPY 4.58T
+7.5% year over year
Net income, FY2025
JPY 108.1B
−25.0% year over year
Free cash flow, FY2025
JPY 856.4B
+58.3% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
2.37M
Shares sold short
Change
−245.5K
−9.4% vs. previous
Days to cover
94.11
At average daily volume

Superinvestors holding TKPHF, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding TKPHF at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Takeda Pharmaceutical Co Ltd insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 5, 2026 (view filing)3:54 PM ETNov 41 dayPlatford Giles RichardPresident, IBUSSaleAmerican Depositary Shares−55.6K$20.90−$1.16M−17.1%270.3K after
Nov 4, 2026 (view filing)5:35 PM ETNov 22 daysBitetti Teresa MariePresident, OBUSSaleAmerican Depositary Shares−46.6K$20.89−$973.7K−17.9%214.5K after
Sep 15, 2026 (view filing)9:12 PM ETSep 141 dayDuprey Lauren RusckowskiChief Transformation OfficerSSaleAmerican Depositary Shares−34.5K$18.54−$640.3K−15.3%191.5K after
Sep 3, 2026 (view filing)9:49 PM ETSep 21 dayPlump Andrew StewartPresident, R&DSSaleAmerican Depositary Shares−116.2K$18.49−$2.15M−44.4%145.5K after10b5-1
Aug 21, 2026 (view filing)4:30 PM ETAug 192 daysPlump Andrew StewartPresident, R&DSSaleAmerican Depositary Shares−19.7K$18.49−$363.3K−7.0%261.7K after10b5-1
Aug 19, 2026 (view filing)4:15 PM ETAug 181 dayGreenway Nicola Deidre PetalChief Human Resources OfficerSSaleAmerican Depositary Shares−13.0K$18.11−$235.1K−24.5%40.0K after
Aug 12, 2026 (view filing)9:54 PM ETAug 102 daysFarajallah Awny Samaan BotrosChief Medical OfficerSSaleAmerican Depositary Shares−14.0K$17.10−$239.5K−10.8%116.2K after
Aug 12, 2026 (view filing)9:53 PM ETAug 102 daysIbrahim Ramy Riad AhmedPresident, PDT BUSSaleAmerican Depositary Shares−7.28K$17.10−$124.4K−6.6%102.6K after
Aug 12, 2026 (view filing)9:53 PM ETAug 102 daysPacheco Rhonda JanicePresident, U.S. Business UnitSSaleAmerican Depositary Shares−16.9K$17.10−$289.0K−8.5%182.5K after
Aug 12, 2026 (view filing)9:51 PM ETAug 102 daysDuprey Lauren RusckowskiChief Transformation OfficerSSaleAmerican Depositary Shares−47.6K$17.10−$813.7K−17.4%226.1K after

Top 10 13F holders, Q2 2026

View all: Top 10 13F holders, Q2 2026

The largest institutional positions in Takeda Pharmaceutical Co Ltd at the end of Q2 2026; share changes are against Q1 2026.

No institution reported holding TKPHF in 13F filings for Q2 2026.

3 members of Congress reported 6 trades in Takeda Pharmaceutical Co Ltd since 2020. Newest filings:

  1. Alan Armstrong

    Senate · OK · Jul 21, 2026

    Buy$1K-$15K

  2. Virginia Foxx

    House · NC · Sep 5, 2023

    Sell$15K-$50K

  3. Daniel S. Goldman

    House · NY · Aug 13, 2023

    Sell$15K-$50K

  4. Daniel S. Goldman

    House · NY · Mar 20, 2023

    Buy$1K-$15K

  5. Virginia Foxx

    House · NC · Mar 3, 2023

    Buy$1K-$15K